{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:47:17Z","timestamp":1787021237029,"version":"build-2736575974"},"reference-count":283,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mutation Research - Reviews in Mutation Research"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.mrrev.2025.108580","type":"journal-article","created":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T16:03:59Z","timestamp":1766678639000},"page":"108580","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Unveiling oral cancer\u2019s molecular blueprint: A novel classification to guide precision therapy"],"prefix":"10.1016","volume":"797","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1496-9846","authenticated-orcid":false,"given":"Manoj","family":"Pandey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mridula","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Rajput","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruhi","family":"Dixit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.mrrev.2025.108580_bib1","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.mrrev.2025.108580_bib2","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1186\/s12885-022-09578-1","article-title":"Burden of cancers in India - estimates of cancer crude incidence, YLLs, YLDs and DALYs for 2021 and 2025 based on National Cancer Registry Program","volume":"22","author":"Kulothungan","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.mrrev.2025.108580_bib3","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.oraloncology.2017.05.004","article-title":"Genetic etiology of oral cancer","volume":"70","author":"Ali","year":"2017","journal-title":"Oral. Oncol."},{"issue":"1","key":"10.1016\/j.mrrev.2025.108580_bib4","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s12957-019-1741-2","article-title":"Mutational spectrum of tobacco associated oral squamous carcinoma and its therapeutic significance","volume":"17","author":"Batta","year":"2019","journal-title":"World J. Surg. Oncol."},{"issue":"8","key":"10.1016\/j.mrrev.2025.108580_bib5","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.oraloncology.2015.05.008","article-title":"Role of miRNA in cancer diagnosis, prognosis, therapy and regulation of its expression by Epstein-Barr virus and human papillomaviruses: With special reference to oral cancer","volume":"51","author":"Chawla","year":"2015","journal-title":"Oral. Oncol."},{"issue":"2","key":"10.1016\/j.mrrev.2025.108580_bib6","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/jcb.29341","article-title":"Single nucleotide polymorphisms in transcription factor genes associated with susceptibility to oral cancer","volume":"121","author":"Damani Shah","year":"2020","journal-title":"J. Cell Biochem"},{"issue":"2","key":"10.1016\/j.mrrev.2025.108580_bib7","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s13193-021-01431-4","article-title":"Molecular Insights into Oral Malignancy","volume":"13","author":"Deshmukh","year":"2022","journal-title":"Indian J. Surg. Oncol."},{"issue":"8","key":"10.1016\/j.mrrev.2025.108580_bib8","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.ijom.2018.01.020","article-title":"Genetic and epigenetic alterations in the tumour, tumour margins, and normal buccal mucosa of patients with oral cancer","volume":"47","author":"Eljabo","year":"2018","journal-title":"Int J. Oral. Maxillofac. Surg."},{"key":"10.1016\/j.mrrev.2025.108580_bib9","doi-asserted-by":"crossref","DOI":"10.1111\/jop.13338","article-title":"Analysis of genetic variants of frequently mutated genes in HPV-negative primary head and neck squamous cell carcinoma, resection margins, local recurrences and corresponding circulating cell-free DNA","author":"Flach","year":"2022","journal-title":"J. Oral. Pathol. Med"},{"issue":"3","key":"10.1016\/j.mrrev.2025.108580_bib10","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1600-0714.2006.00398.x","article-title":"Analysis of apoptosis-associated genes and pathways in oral cancer cells","volume":"35","author":"Gibson","year":"2006","journal-title":"J. Oral. Pathol. Med"},{"issue":"9","key":"10.1016\/j.mrrev.2025.108580_bib11","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/gcc.23076","article-title":"Whole genome duplication in oral squamous cell carcinoma in patients younger than 50\u2009years: implications for prognosis and adverse clinicopathological factors","volume":"61","author":"Satgunaseelan","year":"2022","journal-title":"Genes Chromosomes Cancer"},{"issue":"5","key":"10.1016\/j.mrrev.2025.108580_bib12","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1535-6108(04)00112-6","article-title":"Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression","volume":"5","author":"Chung","year":"2004","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.mrrev.2025.108580_bib13","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/ijc.20197","article-title":"Molecular classification of oral cancer by cDNA microarrays identifies overexpressed genes correlated with nodal metastasis","volume":"110","author":"Warner","year":"2004","journal-title":"Int J. Cancer"},{"issue":"11","key":"10.1016\/j.mrrev.2025.108580_bib14","doi-asserted-by":"crossref","first-page":"9627","DOI":"10.18632\/oncotarget.3301","article-title":"Head and neck cancer subtypes with biological and clinical relevance: Meta-analysis of gene-expression data","volume":"6","author":"De Cecco","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.mrrev.2025.108580_bib15","article-title":"Molecular Subtypes of Oral Squamous Cell Carcinoma Based on Immunosuppression Genes Using a Deep Learning Approach","volume":"9","author":"Li","year":"2021","journal-title":"Front Cell Dev. Biol."},{"issue":"20","key":"10.1016\/j.mrrev.2025.108580_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17203282","article-title":"Molecular characterization of oral squamous cell carcinoma in Mexican patients: a genomic and epidemiological overview","volume":"17","author":"Lopez-Gomez","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.mrrev.2025.108580_bib17","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1186\/1756-0500-7-337","article-title":"Mutation analysis of genes in the EGFR pathway in Head and Neck cancer patients: implications for anti-EGFR treatment response","volume":"7","author":"Boeckx","year":"2014","journal-title":"BMC Res Notes"},{"issue":"45","key":"10.1016\/j.mrrev.2025.108580_bib18","doi-asserted-by":"crossref","first-page":"74362","DOI":"10.18632\/oncotarget.11413","article-title":"Prognostic and predictive value of EGFR in head and neck squamous cell carcinoma","volume":"7","author":"Bossi","year":"2016","journal-title":"Oncotarget"},{"issue":"14","key":"10.1016\/j.mrrev.2025.108580_bib19","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1158\/1078-0432.CCR-19-3997","article-title":"Integrative analysis of multi-omics data identified EGFR and PTGS2 as key nodes in a gene regulatory network related to immune phenotypes in head and neck cancer","volume":"26","author":"Feng","year":"2020","journal-title":"Clin. Cancer Res"},{"issue":"1","key":"10.1016\/j.mrrev.2025.108580_bib20","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12957-018-1308-7","article-title":"Effect of neoadjuvant chemotherapy and its correlation with HPV status, EGFR, Her-2-neu, and GADD45 expression in oral squamous cell carcinoma","volume":"16","author":"Pandey","year":"2018","journal-title":"World J. Surg. Oncol."},{"issue":"5","key":"10.1016\/j.mrrev.2025.108580_bib21","doi-asserted-by":"crossref","first-page":"508","DOI":"10.4149\/neo_2012_065","article-title":"Epidermal growth factor receptor (EGFR) expression and mutations in the EGFR signaling pathway in correlation with anti-EGFR therapy in head and neck squamous cell carcinomas","volume":"59","author":"Smilek","year":"2012","journal-title":"Neoplasma"},{"issue":"6","key":"10.1016\/j.mrrev.2025.108580_bib22","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.oraloncology.2011.03.020","article-title":"Clinical significance of genetic alterations and expression of epidermal growth factor receptor (EGFR) in head and neck squamous cell carcinomas","volume":"47","author":"Szab\u00f3","year":"2011","journal-title":"Oral. Oncol."},{"issue":"1","key":"10.1016\/j.mrrev.2025.108580_bib23","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1186\/s12885-020-07709-0","article-title":"Application of Random Forest and data integration identifies three dysregulated genes and enrichment of Central Carbon Metabolism pathway in Oral Cancer","volume":"20","author":"Mukhopadhyay","year":"2020","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.mrrev.2025.108580_bib24","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1177\/0194599817700371","article-title":"Immunohistochemistry analysis of CD44, EGFR, and p16 in oral cavity and oropharyngeal squamous cell carcinoma","volume":"157","author":"Cohen","year":"2017","journal-title":"Otolaryngol. Head. Neck Surg."},{"issue":"3","key":"10.1016\/j.mrrev.2025.108580_bib25","first-page":"597","article-title":"The immunoexpression of EGFR and Her2\/neu in oral squamous carcinoma","volume":"53","author":"Dragomir","year":"2012","journal-title":"Rom. J. Morphol. Embryol."},{"issue":"3","key":"10.1016\/j.mrrev.2025.108580_bib26","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/jop.12111","article-title":"Immunohistochemical and FISH analysis of EGFR and its prognostic value in patients with oral squamous cell carcinoma","volume":"43","author":"Gr\u00f6be","year":"2014","journal-title":"J. Oral. Pathol. Med"},{"issue":"2","key":"10.1016\/j.mrrev.2025.108580_bib27","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/BF02893450","article-title":"Immunohistochemical expression of EGFR and p-EGFR in oral squamous cell carcinomas","volume":"12","author":"Hiraishi","year":"2006","journal-title":"Pathol. Oncol. Res"},{"issue":"5","key":"10.1016\/j.mrrev.2025.108580_bib28","doi-asserted-by":"crossref","first-page":"e739","DOI":"10.4317\/medoral.17950","article-title":"Immunohistochemical expression of EGFR in oral leukoplakia: association with clinicopathological features and cellular proliferation","volume":"17","author":"Ribeiro","year":"2012","journal-title":"Med Oral. Patol. Oral. Cir. Bucal"},{"issue":"5","key":"10.1016\/j.mrrev.2025.108580_bib29","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/path.5900","article-title":"Integrative analysis of genomic and transcriptomic data of normal, tumour, and co-occurring leukoplakia tissue triads drawn from patients with gingivobuccal oral cancer identifies signatures of tumour initiation and progression","volume":"257","author":"Ghosh","year":"2022","journal-title":"J. Pathol."},{"issue":"1","key":"10.1016\/j.mrrev.2025.108580_bib30","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s13402-013-0161-5","article-title":"Genetic gains and losses in oral squamous cell carcinoma: impact on clinical management","volume":"37","author":"Ribeiro","year":"2014","journal-title":"Cell Oncol (Dordr)"},{"issue":"6","key":"10.1016\/j.mrrev.2025.108580_bib31","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/jop.13303","article-title":"Recurrent copy number alterations involving EGFR, CDKN2A, and CCND1 in oral premalignant lesions","volume":"51","author":"J\u00e4wert","year":"2022","journal-title":"J. Oral. Pathol. Med"},{"issue":"2","key":"10.1016\/j.mrrev.2025.108580_bib32","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/his.12175","article-title":"EGFR expression and copy number changes in low T-stage oral squamous cell carcinomas","volume":"63","author":"R\u00f6ssle","year":"2013","journal-title":"Histopathology"},{"issue":"4","key":"10.1016\/j.mrrev.2025.108580_bib33","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/sj.bjc.6601171","article-title":"Prognostic significance of EGFR and Her-2 in oral cavity cancer in betel quid prevalent area cancer prognosis","volume":"89","author":"Chen","year":"2003","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.mrrev.2025.108580_bib34","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.oraloncology.2016.05.007","article-title":"Co-targeting ALK and EGFR parallel signaling in oral squamous cell carcinoma","volume":"59","author":"Gonzales","year":"2016","journal-title":"Oral. Oncol."},{"issue":"4","key":"10.1016\/j.mrrev.2025.108580_bib35","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1093\/annonc\/mdy040","article-title":"Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and\/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02)","volume":"29","author":"Tahara","year":"2018","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.mrrev.2025.108580_bib36","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.annonc.2022.10.006","article-title":"Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial","volume":"34","author":"Tao","year":"2023","journal-title":"Ann. Oncol."},{"issue":"10166","key":"10.1016\/j.mrrev.2025.108580_bib37","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(18)32779-X","article-title":"Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial","volume":"393","author":"Gillison","year":"2019","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.mrrev.2025.108580_bib38","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S1470-2045(21)00136-4","article-title":"Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial","volume":"22","author":"Sacco","year":"2021","journal-title":"Lancet Oncol."},{"issue":"10","key":"10.1016\/j.mrrev.2025.108580_bib39","doi-asserted-by":"crossref","first-page":"e155","DOI":"10.1016\/j.oraloncology.2009.05.637","article-title":"Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck","volume":"45","author":"Cohen","year":"2009","journal-title":"Oral. Oncol."},{"issue":"11","key":"10.1016\/j.mrrev.2025.108580_bib40","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1016\/j.ejca.2013.03.011","article-title":"A novel serum protein signature associated with resistance to epidermal growth factor receptor tyrosine kinase inhibitors in head and neck squamous cell carcinoma","volume":"49","author":"Box","year":"2013","journal-title":"Eur. J. Cancer"},{"issue":"7","key":"10.1016\/j.mrrev.2025.108580_bib41","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1093\/annonc\/mdv194","article-title":"Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and\/or metastatic head and neck squamous cell carcinoma","volume":"26","author":"Massarelli","year":"2015","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.mrrev.2025.108580_bib42","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.7314\/APJCP.2012.13.6.2891","article-title":"HER2\/neu expression in head and neck squamous cell carcinoma patients is not significantly elevated","volume":"13","author":"Sardari","year":"2012","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"1","key":"10.1016\/j.mrrev.2025.108580_bib43","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2174\/1568009617666170427105417","article-title":"Specific Targeting of HER2-Positive Head and Neck Squamous Cell Carcinoma Line HN5 by Idarubicin-ZHER2 Affibody Conjugate","volume":"19","author":"Ghanemi","year":"2019","journal-title":"Curr. Cancer Drug Targets"},{"issue":"1","key":"10.1016\/j.mrrev.2025.108580_bib44","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-12367-7","article-title":"Dual \"mAb\" HER family blockade in head and neck cancer human cell lines combined with photon therapy","volume":"7","author":"Guy","year":"2017","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.mrrev.2025.108580_bib45","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1158\/1078-0432.CCR-14-1432","article-title":"HER2 as a therapeutic target in head and neck squamous cell carcinoma","volume":"21","author":"Pollock","year":"2015","journal-title":"Clin. Cancer Res"},{"issue":"12","key":"10.1016\/j.mrrev.2025.108580_bib46","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/S1470-2045(21)00584-2","article-title":"Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study","volume":"22","author":"Lakhani","year":"2021","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.mrrev.2025.108580_bib47","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/PPO.0000000000000622","article-title":"HER2 and HER3 as Therapeutic Targets in Head and Neck Cancer","volume":"28","author":"Saddawi-Konefka","year":"2022","journal-title":"Cancer J."},{"issue":"7","key":"10.1016\/j.mrrev.2025.108580_bib48","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1200\/JCO.2008.17.5349","article-title":"Phase I study of lapatinib in combination with chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck","volume":"27","author":"Harrington","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.mrrev.2025.108580_bib49","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1158\/1078-0432.CCR-11-2825","article-title":"A phase II study of lapatinib in recurrent\/metastatic squamous cell carcinoma of the head and neck","volume":"18","author":"de Souza","year":"2012","journal-title":"Clin. Cancer Res"},{"issue":"7","key":"10.1016\/j.mrrev.2025.108580_bib50","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.ejca.2012.11.023","article-title":"Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus-negative disease","volume":"49","author":"Harrington","year":"2013","journal-title":"Eur. J. Cancer"},{"issue":"5","key":"10.1016\/j.mrrev.2025.108580_bib51","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/bjc.2011.237","article-title":"Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck","volume":"105","author":"Del Campo","year":"2011","journal-title":"Br. J. Cancer"},{"issue":"14","key":"10.1016\/j.mrrev.2025.108580_bib52","doi-asserted-by":"crossref","first-page":"64","DOI":"10.14715\/cmb\/2016.62.14.11","article-title":"VEGF mediated signaling in oral cancer","volume":"62","author":"Lin","year":"2016","journal-title":"Cell Mol Biol (Noisylegrand)"},{"issue":"5","key":"10.1016\/j.mrrev.2025.108580_bib53","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/jso.20546","article-title":"High expressions of CD105 and VEGF in early oral cancer predict potential cervical metastasis","volume":"94","author":"Chien","year":"2006","journal-title":"J. Surg. Oncol."},{"issue":"4","key":"10.1016\/j.mrrev.2025.108580_bib54","first-page":"527","article-title":"VEGF and VEGFRs expression in oral squamous cell carcinoma","volume":"50","author":"M\u0103rg\u0103ritescu","year":"2009","journal-title":"Rom. J. Morphol. Embryol."},{"issue":"9","key":"10.1016\/j.mrrev.2025.108580_bib55","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.31557\/APJCP.2022.23.9.3141","article-title":"Alterations in p53 Influence hTERT, VEGF and MMPs Expression in Oral Cancer Patients","volume":"23","author":"Singh","year":"2022","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"4","key":"10.1016\/j.mrrev.2025.108580_bib56","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0060283","article-title":"Impact of VEGF-C gene polymorphisms and environmental factors on oral cancer susceptibility in Taiwan","volume":"8","author":"Chien","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.mrrev.2025.108580_bib57","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1136\/jcp.2007.047662","article-title":"VEGF-C is associated with lymphatic status and invasion in oral cancer","volume":"61","author":"Siriwardena","year":"2008","journal-title":"J. Clin. Pathol."},{"issue":"12","key":"10.1016\/j.mrrev.2025.108580_bib58","doi-asserted-by":"crossref","first-page":"6637","DOI":"10.1007\/s11033-013-2778-x","article-title":"VEGF +936C\/T and +460C\/T gene polymorphisms and oral cancer risk: a meta-analysis","volume":"40","author":"Zhao","year":"2013","journal-title":"Mol. Biol. Rep."},{"issue":"13","key":"10.1016\/j.mrrev.2025.108580_bib59","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23137483","article-title":"Regulation of VEGFA, KRAS, and NFE2L2 Oncogenes by MicroRNAs in Head and Neck Cancer","volume":"23","author":"Cuzziol","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.mrrev.2025.108580_bib60","first-page":"147","article-title":"Immunohistochemical expression of COX-2, Ki-67, Bcl-2, Bax, VEGF and CD105 according to histological grading in oral squamous cell carcinoma","volume":"56","author":"Escobar","year":"2023","journal-title":"Rev. Esp. Patol."},{"key":"10.1016\/j.mrrev.2025.108580_bib61","doi-asserted-by":"crossref","first-page":"5163","DOI":"10.2147\/CMAR.S201943","article-title":"c-MYC expression in T (III\/IV) stage oral squamous cell carcinoma (OSCC) patients","volume":"11","author":"Lin","year":"2019","journal-title":"Cancer Manag Res"},{"issue":"7","key":"10.1016\/j.mrrev.2025.108580_bib62","article-title":"C-Myc Expression in Oral Squamous Cell Carcinoma: Molecular Mechanisms in Cell Survival and Cancer Progression","volume":"15","author":"Marconi","year":"2022","journal-title":"Pharm. (Basel)"},{"issue":"3","key":"10.1016\/j.mrrev.2025.108580_bib63","doi-asserted-by":"crossref","first-page":"325","DOI":"10.4103\/jomfp.JOMFP_197_18","article-title":"Bcl-2 and c-Myc expression in oral dysplasia and oral squamous cell carcinoma: An immunohistochemical study to assess tumor progression","volume":"22","author":"Pallavi","year":"2018","journal-title":"J. Oral. Maxillofac. Pathol."},{"issue":"9","key":"10.1016\/j.mrrev.2025.108580_bib64","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.ijom.2010.05.007","article-title":"Cancer genes alterations and HPV infection in oral squamous cell carcinoma","volume":"39","author":"Popovi\u0107","year":"2010","journal-title":"Int J. Oral. Maxillofac. Surg."},{"issue":"4","key":"10.1016\/j.mrrev.2025.108580_bib65","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1111\/odi.13814","article-title":"Evaluation of HPV and EBV in OSCC and the expression of p53, p16, E-cadherin, COX-2, MYC, and MLH1","volume":"28","author":"de Lima","year":"2022","journal-title":"Oral. Dis."},{"issue":"9","key":"10.1016\/j.mrrev.2025.108580_bib66","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s12032-017-1010-6","article-title":"Amplification of EGFR and cyclin D1 genes associated with human papillomavirus infection in oral squamous cell carcinoma","volume":"34","author":"Chuerduangphui","year":"2017","journal-title":"Med. Oncol."},{"issue":"4","key":"10.1016\/j.mrrev.2025.108580_bib67","article-title":"Bioinformatics analysis of miRNA and its associated genes to identify potential biomarkers of oral submucous fibrosis and oral malignancy","volume":"6","author":"Mohanan","year":"2023","journal-title":"Cancer Rep"},{"issue":"5","key":"10.1016\/j.mrrev.2025.108580_bib68","first-page":"1750","article-title":"The gene ratios c-MYC:cyclin-dependent kinase (CDK)N2A and CCND1:CDKN2A correlate with poor prognosis in squamous cell carcinoma of the head and neck","volume":"9","author":"Akervall","year":"2003","journal-title":"Clin. Cancer Res"},{"issue":"13","key":"10.1016\/j.mrrev.2025.108580_bib69","doi-asserted-by":"crossref","first-page":"8992","DOI":"10.1021\/acs.jmedchem.1c00093","article-title":"Discovery of an Orally Efficacious MYC Inhibitor for Liver Cancer Using a GNMT-Based High-Throughput Screening System and Structure-Activity Relationship Analysis","volume":"64","author":"Kant","year":"2021","journal-title":"J. Med Chem."},{"issue":"1","key":"10.1016\/j.mrrev.2025.108580_bib70","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2130583","article-title":"Therapeutic Targeting of MYC in Head and Neck Squamous Cell Carcinoma","volume":"11","author":"Liu","year":"2022","journal-title":"Oncoimmunology"},{"issue":"8","key":"10.1016\/j.mrrev.2025.108580_bib71","article-title":"A Selective Small-Molecule c-Myc Degrader Potently Regresses Lethal c-Myc Overexpressing Tumors","volume":"9","author":"Xu","year":"2022","journal-title":"Adv. Sci. (Weinh. )"},{"issue":"11","key":"10.1016\/j.mrrev.2025.108580_bib72","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/s41419-019-2098-8","article-title":"Cisplatin exposure causes c-Myc-dependent resistance to CDK4\/6 inhibition in HPV-negative head and neck squamous cell carcinoma","volume":"10","author":"Robinson","year":"2019","journal-title":"Cell Death Dis."},{"issue":"4","key":"10.1016\/j.mrrev.2025.108580_bib73","doi-asserted-by":"crossref","first-page":"e366","DOI":"10.4317\/medoral.25298","article-title":"Connexin 43, Bcl-2, Bax, Ki67, and E-cadherin patterns in oral squamous cell carcinoma and its relationship with GJA1 rs12197797 C\/G","volume":"27","author":"Segura","year":"2022","journal-title":"Med Oral. Patol. Oral. Cir. Bucal"},{"issue":"1","key":"10.1016\/j.mrrev.2025.108580_bib74","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2334\/josnusd.51.117","article-title":"Immunohistochemical expression of PCNA, p53, bax and bcl-2 in oral lichen planus and epithelial dysplasia","volume":"51","author":"Sousa","year":"2009","journal-title":"J. Oral. Sci."},{"issue":"2","key":"10.1016\/j.mrrev.2025.108580_bib75","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/BF03033719","article-title":"Expression of bcl-2 and bax in chewing tobacco-induced oral cancers and oral lesions from India","volume":"8","author":"Teni","year":"2002","journal-title":"Pathol. Oncol. Res."},{"issue":"8","key":"10.1016\/j.mrrev.2025.108580_bib76","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41419-019-1790-z","article-title":"Raptinal bypasses BAX, BAK, and BOK for mitochondrial outer membrane permeabilization and intrinsic apoptosis","volume":"10","author":"Heimer","year":"2019","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.mrrev.2025.108580_bib77","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/hed.25471","article-title":"Role and regulation of proapoptotic Bax in oral squamous cell carcinoma and drug resistance","volume":"41","author":"Alam","year":"2019","journal-title":"Head. Neck"},{"issue":"7","key":"10.1016\/j.mrrev.2025.108580_bib78","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21072360","article-title":"Overexpression of platelet-derived growth factor and its receptor are correlated with oral tumorigenesis and poor prognosis in oral squamous cell carcinoma","volume":"21","author":"Lin","year":"2020","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.mrrev.2025.108580_bib79","doi-asserted-by":"crossref","first-page":"552","DOI":"10.3389\/fonc.2020.00552","article-title":"Activation PDGFR-\u03b1\/AKT Mediated Signaling Pathways in Oral Squamous Cell Carcinoma by Mesenchymal Stem\/Stromal Cells Promotes Anti-apoptosis and Decreased Sensitivity to Cisplatin","volume":"10","author":"Wang","year":"2020","journal-title":"Front Oncol."},{"issue":"2","key":"10.1016\/j.mrrev.2025.108580_bib80","doi-asserted-by":"crossref","first-page":"591","DOI":"10.21873\/anticanres.16195","article-title":"Prognostic Value of WNT1, NOTCH1, PDGFR\u03b2, and CXCR4 in Oral Squamous Cell Carcinoma","volume":"43","author":"Cierpikowski","year":"2023","journal-title":"Anticancer Res"},{"issue":"2","key":"10.1016\/j.mrrev.2025.108580_bib81","first-page":"795","article-title":"PDGFR\u03b1\/HER2 and PDGFR\u03b1\/p53 Co-expression in Oral Squamous Cell Carcinoma","volume":"38","author":"Cierpikowski","year":"2018","journal-title":"Anticancer Res"},{"issue":"3","key":"10.1016\/j.mrrev.2025.108580_bib82","doi-asserted-by":"crossref","first-page":"818","DOI":"10.7150\/ijbs.91786","article-title":"IGF2BP2 promotes cell invasion and epithelial-mesenchymal transition through Src-mediated upregulation of EREG in oral cancer","volume":"20","author":"Lin","year":"2024","journal-title":"Int J. Biol. Sci."},{"issue":"11","key":"10.1016\/j.mrrev.2025.108580_bib83","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0028053","article-title":"CD133\/Src axis mediates tumor initiating property and epithelial-mesenchymal transition of head and neck cancer","volume":"6","author":"Chen","year":"2011","journal-title":"PLoS One"},{"issue":"20","key":"10.1016\/j.mrrev.2025.108580_bib84","doi-asserted-by":"crossref","first-page":"32783","DOI":"10.18632\/oncotarget.15824","article-title":"MMP-11 promoted the oral cancer migration and Fak\/Src activation","volume":"8","author":"Hsin","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.mrrev.2025.108580_bib85","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1186\/1471-2407-14-442","article-title":"Src-homology 2 domain-containing tyrosine phosphatase 2 promotes oral cancer invasion and metastasis","volume":"14","author":"Wang","year":"2014","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.mrrev.2025.108580_bib86","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12929-022-00824-z","article-title":"MicroRNA-485-5p targets keratin 17 to regulate oral cancer stemness and chemoresistance via the integrin\/FAK\/Src\/ERK\/\u03b2-catenin pathway","volume":"29","author":"Jang","year":"2022","journal-title":"J. Biomed. Sci."},{"issue":"12","key":"10.1016\/j.mrrev.2025.108580_bib87","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1593\/neo.08854","article-title":"Src family kinases mediate betel quid-induced oral cancer cell motility and could be a biomarker for early invasion in oral squamous cell carcinoma","volume":"10","author":"Chen","year":"2008","journal-title":"Neoplasia"},{"issue":"1","key":"10.1016\/j.mrrev.2025.108580_bib88","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.bbrc.2010.07.042","article-title":"Betel quid extract promotes oral cancer cell migration by activating a muscarinic M4 receptor-mediated signaling cascade involving SFKs and ERK1\/2","volume":"399","author":"Chiu","year":"2010","journal-title":"Biochem Biophys. Res Commun."},{"issue":"1","key":"10.1016\/j.mrrev.2025.108580_bib89","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13045-018-0623-3","article-title":"Combating head and neck cancer metastases by targeting Src using multifunctional nanoparticle-based saracatinib","volume":"11","author":"Lang","year":"2018","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.mrrev.2025.108580_bib90","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S1368-8375(99)00058-5","article-title":"ras gene mutations in oral cancer in eastern India","volume":"36","author":"Das","year":"2000","journal-title":"Oral. Oncol."},{"issue":"1","key":"10.1016\/j.mrrev.2025.108580_bib91","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s12105-024-01623-8","article-title":"Unraveling the Genetic Web: H-Ras Expression and Mutation in Oral Squamous Cell Carcinoma-A Systematic Review","volume":"18","author":"Devi","year":"2024","journal-title":"Head. Neck Pathol."},{"issue":"4","key":"10.1016\/j.mrrev.2025.108580_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.jormas.2024.102120","article-title":"Molecular profiling of oral epithelial dysplasia and oral squamous cell carcinoma using next generation sequencing","volume":"126","author":"Krishnan","year":"2024","journal-title":"J. Stomatol Oral. Maxillofac. Surg."},{"issue":"5","key":"10.1016\/j.mrrev.2025.108580_bib93","first-page":"971","article-title":"Detection of a rare point mutation at codon 59 and relatively high incidence of H-ras mutation in Indian oral cancer","volume":"13","author":"Munirajan","year":"1998","journal-title":"Int J. Oncol."},{"issue":"6","key":"10.1016\/j.mrrev.2025.108580_bib94","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1080\/10520295.2023.2196731","article-title":"RAS gene mutations and histomorphometric measurements in oral squamous cell carcinoma","volume":"98","author":"Mustansar","year":"2023","journal-title":"Biotech. Histochem"},{"issue":"2","key":"10.1016\/j.mrrev.2025.108580_bib95","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s12253-016-0114-1","article-title":"Studies on the Contribution of Cox-2 Expression in the Progression of Oral Squamous Cell Carcinoma and H-Ras Activation","volume":"23","author":"Moazeni-Roodi","year":"2017","journal-title":"Pathol. Oncol. Res"},{"issue":"2","key":"10.1016\/j.mrrev.2025.108580_bib96","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s12105-022-01491-0","article-title":"Analysis of H-ras Mutations and Immunohistochemistry in Recurrence Cases of High-Grade Oral Squamous Cell Carcinoma","volume":"17","author":"Hamidavi Asl","year":"2023","journal-title":"Head. Neck Pathol."},{"issue":"6","key":"10.1016\/j.mrrev.2025.108580_bib97","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1600-0714.1995.tb01178.x","article-title":"Elevated ras p21 expression in oral premalignant lesions and squamous cell carcinoma in Taiwan","volume":"24","author":"Kuo","year":"1995","journal-title":"J. Oral. Pathol. Med"},{"issue":"7","key":"10.1016\/j.mrrev.2025.108580_bib98","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/jcp.25269","article-title":"MicroRNAs: Modulators of the Ras Oncogenes in Oral Cancer","volume":"231","author":"Murugan","year":"2016","journal-title":"J. Cell Physiol."},{"issue":"11","key":"10.1016\/j.mrrev.2025.108580_bib99","doi-asserted-by":"crossref","first-page":"9059","DOI":"10.1007\/s13277-015-3659-9","article-title":"Lip cancer and pre-cancerous lesions harbor TP53 mutations, exhibit allelic loss at 9p, 9q, and 17p, but no BRAFV600E mutations","volume":"36","author":"Correa","year":"2015","journal-title":"Tumour Biol."},{"issue":"3","key":"10.1016\/j.mrrev.2025.108580_bib100","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1080\/09674845.2014.11669972","article-title":"ERK and RAF1 genes: analysis of methylation and expression profiles in patients with oral squamous cell carcinoma","volume":"71","author":"Kordi-Tamandani","year":"2014","journal-title":"Br. J. Biomed. Sci."},{"issue":"8","key":"10.1016\/j.mrrev.2025.108580_bib101","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41419-022-05152-6","article-title":"Identification of a BRAF\/PA28\u03b3\/MEK1 signaling axis and its role in epithelial-mesenchymal transition in oral submucous fibrosis","volume":"13","author":"Xie","year":"2022","journal-title":"Cell Death Dis."},{"issue":"5","key":"10.1016\/j.mrrev.2025.108580_bib102","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s12094-016-1565-2","article-title":"CDK4 in lung, and head and neck cancers in old age: evaluation as a biomarker","volume":"19","author":"Banerjee","year":"2017","journal-title":"Clin. Transl. Oncol."},{"issue":"1","key":"10.1016\/j.mrrev.2025.108580_bib103","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s00432-022-04358-7","article-title":"Mutational profiles of head and neck squamous cell carcinomas based upon human papillomavirus status in the Veterans Affairs National Precision Oncology Program","volume":"149","author":"Doerstling","year":"2023","journal-title":"J. Cancer Res Clin. Oncol."},{"issue":"2","key":"10.1016\/j.mrrev.2025.108580_bib104","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.oraloncology.2004.05.003","article-title":"Down-regulation of Cdk inhibitor p27 in oral squamous cell carcinoma","volume":"41","author":"Kudo","year":"2005","journal-title":"Oral. Oncol."},{"issue":"3","key":"10.1016\/j.mrrev.2025.108580_bib105","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.ijrobp.2019.06.2531","article-title":"Inhibition of CDK4\/CDK6 Enhances Radiosensitivity of HPV Negative Head and Neck Squamous Cell Carcinomas","volume":"105","author":"G\u00f6ttgens","year":"2019","journal-title":"Int J. Radiat. Oncol. Biol. Phys."},{"issue":"12","key":"10.1016\/j.mrrev.2025.108580_bib106","doi-asserted-by":"crossref","first-page":"14803","DOI":"10.18632\/oncotarget.7543","article-title":"The CDK4\/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma","volume":"7","author":"Ku","year":"2016","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/j.mrrev.2025.108580_bib107","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9103214","article-title":"CDK 4\/6 inhibition overcomes acquired and inherent resistance to PI3K\u03b1 inhibition in pre-clinical models of head and neck squamous cell carcinoma","volume":"9","author":"Remer","year":"2020","journal-title":"J. Clin. Med"},{"issue":"3","key":"10.1016\/j.mrrev.2025.108580_bib108","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/CCO.0000000000000513","article-title":"Potential role of cyclin-dependent kinase 4\/6 inhibitors in the treatment of squamous cell carcinoma of the head and neck","volume":"31","author":"van Caloen","year":"2019","journal-title":"Curr. Opin. Oncol."},{"issue":"6","key":"10.1016\/j.mrrev.2025.108580_bib109","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13061251","article-title":"Preclinical Evaluation of the Association of the Cyclin-Dependent Kinase 4\/6 Inhibitor, Ribociclib, and Cetuximab in Squamous Cell Carcinoma of the Head and Neck","volume":"13","author":"van Caloen","year":"2021","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.mrrev.2025.108580_bib110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0093102","article-title":"Novel insight into mutational landscape of head and neck squamous cell carcinoma","volume":"9","author":"Gaykalova","year":"2014","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.mrrev.2025.108580_bib111","doi-asserted-by":"crossref","first-page":"881","DOI":"10.17219\/acem\/64000","article-title":"The Notch signaling pathway in head and neck squamous cell carcinoma: a meta-analysis","volume":"26","author":"Zhao","year":"2017","journal-title":"Adv. Clin. Exp. Med."},{"issue":"11","key":"10.1016\/j.mrrev.2025.108580_bib112","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.1245\/s10434-010-1118-9","article-title":"Association of high levels of Jagged-1 and Notch-1 expression with poor prognosis in head and neck cancer","volume":"17","author":"Lin","year":"2010","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.mrrev.2025.108580_bib113","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2020.105003","article-title":"Impact of notch signaling on the prognosis of patients with head and neck squamous cell carcinoma","volume":"110","author":"Grilli","year":"2020","journal-title":"Oral. Oncol."},{"issue":"4","key":"10.1016\/j.mrrev.2025.108580_bib114","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1158\/1940-6207.CAPR-14-0366","article-title":"Cleaved NOTCH1 Expression Pattern in Head and Neck Squamous Cell Carcinoma Is Associated with NOTCH1 Mutation, HPV Status, and High-Risk Features","volume":"8","author":"Rettig","year":"2015","journal-title":"Cancer Prev Res (Phila)"},{"issue":"2","key":"10.1016\/j.mrrev.2025.108580_bib115","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.yexcr.2018.09.019","article-title":"Loss of Notch1 predisposes oro-esophageal epithelium to tumorigenesis","volume":"372","author":"Sawangarun","year":"2018","journal-title":"Exp. Cell Res"},{"issue":"24","key":"10.1016\/j.mrrev.2025.108580_bib116","doi-asserted-by":"crossref","first-page":"6308","DOI":"10.1158\/1078-0432.CCR-17-3535","article-title":"Loss of function of canonical notch signaling drives head and neck carcinogenesis","volume":"24","author":"Nyman","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"26","key":"10.1016\/j.mrrev.2025.108580_bib117","doi-asserted-by":"crossref","first-page":"17766","DOI":"10.1074\/jbc.M109.003111","article-title":"Distinct biological roles for the notch ligands Jagged-1 and Jagged-2","volume":"284","author":"Choi","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.mrrev.2025.108580_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2024.106717","article-title":"Mutation detection in saliva from oral cancer patients","volume":"151","author":"Ahmed","year":"2024","journal-title":"Oral. Oncol."},{"issue":"1","key":"10.1016\/j.mrrev.2025.108580_bib119","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-30238-7","article-title":"Identification and characterization of TP53 gene Allele Dropout in Li-Fraumeni syndrome and Oral cancer cohorts","volume":"8","author":"Haque","year":"2018","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.mrrev.2025.108580_bib120","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100153","article-title":"Abnormal p53 Immunohistochemical Patterns Shed Light on the Aggressiveness of Oral Epithelial Dysplasia","volume":"36","author":"Novack","year":"2023","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.mrrev.2025.108580_bib121","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.oraloncology.2016.05.014","article-title":"Unraveling the oral cancer lncRNAome: Identification of novel lncRNAs associated with malignant progression and HPV infection","volume":"59","author":"Nohata","year":"2016","journal-title":"Oral. Oncol."},{"issue":"1","key":"10.1016\/j.mrrev.2025.108580_bib122","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1186\/s12903-023-03316-0","article-title":"Systematic evaluation of TP53 codon 72 polymorphism associated with onset and progression of oral potentially malignant disorders","volume":"23","author":"Li","year":"2023","journal-title":"BMC Oral. Health"},{"issue":"3","key":"10.1016\/j.mrrev.2025.108580_bib123","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/mc.22543","article-title":"Gender specific association of TP53 polymorphisms (EX4 215G>C Arg72Pro, IVS3+40-41ins16, and IVS6+62G>A), with risk of oral cancer subtypes and overall survival of the patients","volume":"56","author":"Nagam","year":"2017","journal-title":"Mol. Carcinog."},{"issue":"5","key":"10.1016\/j.mrrev.2025.108580_bib124","doi-asserted-by":"crossref","DOI":"10.1177\/1010428317699113","article-title":"Study of the TP53 codon 72 polymorphism in oral cancer and oral potentially malignant disorders in Argentine patients","volume":"39","author":"Zarate","year":"2017","journal-title":"Tumour Biol."},{"issue":"7","key":"10.1016\/j.mrrev.2025.108580_bib125","doi-asserted-by":"crossref","first-page":"E267","DOI":"10.1002\/lary.24595","article-title":"TP53 and CDKN2a mutations in never-smoker oral tongue squamous cell carcinoma","volume":"124","author":"Heaton","year":"2014","journal-title":"Laryngoscope"},{"issue":"1","key":"10.1016\/j.mrrev.2025.108580_bib126","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1186\/s12903-021-01981-7","article-title":"Oral cancer among Khat users: finding evidence from DNA analysis of nine cancer-related gene mutations","volume":"21","author":"Alshahrani","year":"2021","journal-title":"BMC Oral. Health"},{"issue":"2","key":"10.1016\/j.mrrev.2025.108580_bib127","doi-asserted-by":"crossref","first-page":"278","DOI":"10.4103\/jcrt.jcrt_1963_21","article-title":"Expression of TP53 in oral squamous cell carcinoma and its correlation with adverse histopathological features","volume":"19","author":"Giri","year":"2023","journal-title":"J. Cancer Res Ther."},{"key":"10.1016\/j.mrrev.2025.108580_bib128","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s41199-019-0045-0","article-title":"Genomic and human papillomavirus profiling of an oral cancer cohort identifies TP53 as a predictor of overall survival","volume":"4","author":"Mundi","year":"2019","journal-title":"Cancers Head. Neck"},{"issue":"1","key":"10.1016\/j.mrrev.2025.108580_bib129","first-page":"163","article-title":"Retinoblastoma and p53 protein expression in pre-malignant oral lesions and oral squamous cell carcinoma","volume":"6","author":"de Oliveira","year":"2012","journal-title":"Mol. Med Rep."},{"key":"10.1016\/j.mrrev.2025.108580_bib130","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.oraloncology.2018.06.006","article-title":"Frequent HPV-independent p16\/INK4A overexpression in head and neck cancer","volume":"83","author":"Lechner","year":"2018","journal-title":"Oral. Oncol."},{"issue":"5","key":"10.1016\/j.mrrev.2025.108580_bib131","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/s00405-020-05891-2","article-title":"CDK4\/6 inhibitors in P16\/HPV16-negative squamous cell carcinoma of the head and neck","volume":"277","author":"Billard-Sandu","year":"2020","journal-title":"Eur. Arch. Otorhinolaryngol."},{"issue":"8","key":"10.1016\/j.mrrev.2025.108580_bib132","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1002\/mc.23556","article-title":"CDK4\/6 and autophagy inhibitors synergize to suppress the growth of human head and neck squamous cell carcinomas","volume":"62","author":"Duah","year":"2023","journal-title":"Mol. Carcinog."},{"issue":"3","key":"10.1016\/j.mrrev.2025.108580_bib133","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1007\/s13277-015-4179-3","article-title":"Combination of genetic variants in cyclin D1 and retinoblastoma genes predict clinical outcome in oral cancer patients","volume":"37","author":"Murali","year":"2016","journal-title":"Tumour Biol."},{"issue":"2","key":"10.1016\/j.mrrev.2025.108580_bib134","first-page":"213","article-title":"Selected CDKN2A and MDM2 polymorphisms in oral cavity cancer","volume":"67","author":"Ga\u017adzicka","year":"2020","journal-title":"Acta Biochim Pol."},{"key":"10.1016\/j.mrrev.2025.108580_bib135","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.oraloncology.2017.07.030","article-title":"Role of CDKN2A\/p16 expression in the prognostication of oral squamous cell carcinoma","volume":"73","author":"Padhi","year":"2017","journal-title":"Oral. Oncol."},{"issue":"6","key":"10.1016\/j.mrrev.2025.108580_bib136","doi-asserted-by":"crossref","DOI":"10.3390\/biom11060818","article-title":"Detection of PIK3CA Gene Mutation in Head and Neck Squamous Cell Carcinoma Using Droplet Digital PCR and RT-qPCR","volume":"11","author":"Borkowska","year":"2021","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.mrrev.2025.108580_bib137","article-title":"Report of an extremely rare case of BRCA-positive head and neck cancer: a new disease on the horizon?","volume":"17","author":"Karandikar","year":"2025","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.mrrev.2025.108580_bib138","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3324\/haematol.2021.279981","article-title":"Genotype-phenotype and outcome associations in patients with Fanconi anemia: the National Cancer Institute cohort","volume":"108","author":"Altintas","year":"2023","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.mrrev.2025.108580_bib139","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1158\/1535-7163.MCT-16-0457","article-title":"The FA\/BRCA Pathway Identified as the Major Predictor of Cisplatin Response in Head and Neck Cancer by Functional Genomics","volume":"16","author":"Martens-de Kemp","year":"2017","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.mrrev.2025.108580_bib140","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1756-9966-33-40","article-title":"Restoration of E-cadherin expression by selective Cox-2 inhibition and the clinical relevance of the epithelial-to-mesenchymal transition in head and neck squamous cell carcinoma","volume":"33","author":"Fujii","year":"2014","journal-title":"J. Exp. Clin. Cancer Res"},{"key":"10.1016\/j.mrrev.2025.108580_bib141","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2020.101697","article-title":"Epigenetic reprogramming of epithelial-mesenchymal transition promotes ferroptosis of head and neck cancer","volume":"37","author":"Lee","year":"2020","journal-title":"Redox Biol."},{"issue":"8","key":"10.1016\/j.mrrev.2025.108580_bib142","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/jop.12413","article-title":"Overexpression of Bcl-2, SOCS 1, 3 and Cdh 1, 2 are associated with the early neoplasic changes in modified 4-nitroquinoline 1-oxide-induced murine oral cancer model","volume":"45","author":"Cabrera Ortega","year":"2016","journal-title":"J. Oral. Pathol. Med."},{"issue":"1","key":"10.1016\/j.mrrev.2025.108580_bib143","article-title":"CXCR7 promotes migration and invasion in head and neck squamous cell carcinoma by upregulating TGF-\u03b21\/Smad2\/3 signaling","volume":"9","author":"Kim","year":"2019","journal-title":"Sci. Rep."},{"issue":"1-2","key":"10.1016\/j.mrrev.2025.108580_bib144","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.canlet.2006.01.003","article-title":"Disruption of transforming growth factor beta-Smad signaling pathway in head and neck squamous cell carcinoma as evidenced by mutations of SMAD2 and SMAD4","volume":"245","author":"Qiu","year":"2007","journal-title":"Cancer Lett."},{"issue":"5","key":"10.1016\/j.mrrev.2025.108580_bib145","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/jop.12985","article-title":"Relevance and actionable mutational spectrum in oral squamous cell carcinoma","volume":"49","author":"Jayaprakash","year":"2020","journal-title":"J. Oral. Pathol. Med."},{"issue":"2","key":"10.1016\/j.mrrev.2025.108580_bib146","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3727\/000000003108748612","article-title":"Frequent alterations of Smad signaling in human head and neck squamous cell carcinomas: a tissue microarray analysis","volume":"14","author":"Xie","year":"2003","journal-title":"Oncol. Res."},{"issue":"18","key":"10.1016\/j.mrrev.2025.108580_bib147","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1038\/sj.onc.1209291","article-title":"Activation of Smad signaling enhances collagenase-3 (MMP-13) expression and invasion of head and neck squamous carcinoma cells","volume":"25","author":"Leivonen","year":"2006","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.mrrev.2025.108580_bib148","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1099\/jmm.0.000898","article-title":"Impact of HPV infection on gene expression and methylation in oral cancer patients","volume":"68","author":"Prawdzic Se\u0144kowska","year":"2019","journal-title":"J. Med. Microbiol."},{"key":"10.1016\/j.mrrev.2025.108580_bib149","article-title":"Exome Sequencing for Head and Neck Cancer Predisposition Genes","author":"Yu","year":"2025","journal-title":"medRxiv"},{"issue":"2","key":"10.1016\/j.mrrev.2025.108580_bib150","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/modpathol.2017.128","article-title":"Analysis of clinically relevant somatic mutations in high-risk head and neck cutaneous squamous cell carcinoma","volume":"31","author":"Zilberg","year":"2018","journal-title":"Mod. Pathol."},{"issue":"8","key":"10.1016\/j.mrrev.2025.108580_bib151","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1034\/j.1600-0714.2003.00132.x","article-title":"Loss of heterozygosity at APC and MCC genes of oral cancer and leukoplakia tissues from Indian tobacco chewers","volume":"32","author":"Sikdar","year":"2003","journal-title":"J. Oral. Pathol. Med."},{"key":"10.1016\/j.mrrev.2025.108580_bib152","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2021.105369","article-title":"Targeted DNA profiling and the prevalence of NTRK aberrations in Chinese patients with head and neck cancer","volume":"119","author":"Xu","year":"2021","journal-title":"Oral. Oncol."},{"issue":"9","key":"10.1016\/j.mrrev.2025.108580_bib153","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.4161\/epi.29785","article-title":"Promoter hypermethylation using 24-gene array in early head and neck cancer: better outcome in oral than in oropharyngeal cancer","volume":"9","author":"Noorlag","year":"2014","journal-title":"Epigenetics"},{"issue":"11","key":"10.1016\/j.mrrev.2025.108580_bib154","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.7150\/jca.24477","article-title":"Aberrant DNA methylation of the p16, APC, MGMT, TIMP3 and CDH1 gene promoters in tumours and the surgical margins of patients with oral cavity cancer","volume":"9","author":"Strzelczyk","year":"2018","journal-title":"J. Cancer"},{"issue":"2","key":"10.1016\/j.mrrev.2025.108580_bib155","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/jcp-2023-209059","article-title":"PD-L1 expression in recurrent or metastatic head and neck squamous cell carcinoma in China (EXCEED study): a multicentre retrospective study","volume":"78","author":"Lu","year":"2025","journal-title":"J. Clin. Pathol."},{"issue":"1","key":"10.1016\/j.mrrev.2025.108580_bib156","doi-asserted-by":"crossref","first-page":"46","DOI":"10.4103\/jcrt.jcrt_1239_22","article-title":"PD-L1 expression in head and neck squamous cell carcinoma and its clinical significance: A prospective observational study from a tertiary care centre","volume":"20","author":"Kilaru","year":"2024","journal-title":"J. Cancer Res Ther."},{"issue":"4","key":"10.1016\/j.mrrev.2025.108580_bib157","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s12105-023-01590-6","article-title":"Assessing PD-L1 Expression in Head and Neck Squamous Cell Carcinoma: Trials and Tribulations","volume":"17","author":"Bill","year":"2023","journal-title":"Head. Neck Pathol."},{"issue":"18","key":"10.1016\/j.mrrev.2025.108580_bib158","doi-asserted-by":"crossref","DOI":"10.1172\/JCI161400","article-title":"Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-\u03b2 blockade in HPV-unrelated head and neck cancer","volume":"132","author":"Redman","year":"2022","journal-title":"J. Clin. Invest"},{"issue":"10","key":"10.1016\/j.mrrev.2025.108580_bib159","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1001\/jamaoto.2021.2191","article-title":"Neoadjuvant PD-1\/PD-L1 Inhibitors for Resectable Head and Neck Cancer: A Systematic Review and Meta-analysis","volume":"147","author":"Masarwy","year":"2021","journal-title":"JAMA Otolaryngol. Head. Neck Surg."},{"issue":"3","key":"10.1016\/j.mrrev.2025.108580_bib160","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.immuni.2024.02.007","article-title":"CD4(+) T cell activation distinguishes response to anti-PD-L1+anti-CTLA4 therapy from anti-PD-L1 monotherapy","volume":"57","author":"Franken","year":"2024","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.mrrev.2025.108580_bib161","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.oraloncology.2014.10.010","article-title":"Rationale for combined blockade of PD-1 and CTLA-4 in advanced head and neck squamous cell cancer\u2014review of current data","volume":"51","author":"Swanson","year":"2015","journal-title":"Oral. Oncol."},{"issue":"1","key":"10.1016\/j.mrrev.2025.108580_bib162","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/annonc\/mdy495","article-title":"Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic","volume":"30","author":"Chan","year":"2019","journal-title":"Ann. Oncol."},{"issue":"9","key":"10.1016\/j.mrrev.2025.108580_bib163","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.7212","article-title":"Enhanced CTLA-4 blockade anti-tumor immunity with APG-157combination in a murine head and neck cancer","volume":"13","author":"Shin","year":"2024","journal-title":"Cancer Med"},{"issue":"3","key":"10.1016\/j.mrrev.2025.108580_bib164","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.annonc.2022.12.008","article-title":"Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study","volume":"34","author":"Psyrri","year":"2023","journal-title":"Ann. Oncol."},{"issue":"7","key":"10.1016\/j.mrrev.2025.108580_bib165","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1016\/j.ymthe.2023.02.023","article-title":"CTLA-4 blockade induces tumor pyroptosis via CD8(+) T cells in head and neck squamous cell carcinoma","volume":"31","author":"Wang","year":"2023","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.mrrev.2025.108580_bib166","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1186\/s12957-021-02423-y","article-title":"A systematic review of proteomic biomarkers in oral squamous cell cancer","volume":"19","author":"Pillai","year":"2021","journal-title":"World J. Surg. Oncol."},{"issue":"3","key":"10.1016\/j.mrrev.2025.108580_bib167","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1093\/jjco\/hyac185","article-title":"Preoperative serum interleukin-6 level in head and neck cancer reflects systemic inflammatory response and is a predictor of postoperative prognosis","volume":"53","author":"Imai","year":"2023","journal-title":"Jpn J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.mrrev.2025.108580_bib168","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1046\/j.1365-2273.2001.00475.x","article-title":"Interleukins 7 and 12 are expressed in head and neck squamous cancer","volume":"26","author":"Paleri","year":"2001","journal-title":"Clin. Otolaryngol. Allied Sci."},{"issue":"1","key":"10.1016\/j.mrrev.2025.108580_bib169","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00784-021-04017-0","article-title":"Salivary IL-8 as a putative predictive biomarker of radiotherapy response in head and neck cancer patients","volume":"26","author":"Principe","year":"2022","journal-title":"Clin. Oral. Invest."},{"issue":"1","key":"10.1016\/j.mrrev.2025.108580_bib170","doi-asserted-by":"crossref","first-page":"132","DOI":"10.3109\/00016489609137726","article-title":"IL-1 and TNF-alpha but no IL-2 expression is found in squamous cell carcinomas of the head and neck by RT-PCR","volume":"116","author":"Knerer","year":"1996","journal-title":"Acta Otolaryngol."},{"issue":"1","key":"10.1016\/j.mrrev.2025.108580_bib171","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16010223","article-title":"Aspirin and Cancer Survival: An Analysis of Molecular Mechanisms","volume":"16","author":"Pandey","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.mrrev.2025.108580_bib172","first-page":"e268","article-title":"The role of cytokines in head and neck squamous cell carcinoma: A review","volume":"171","author":"Ralli","year":"2020","journal-title":"Clin. Ter."},{"issue":"4","key":"10.1016\/j.mrrev.2025.108580_bib173","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.oooo.2016.05.020","article-title":"Cytokines in saliva increase in head and neck cancer patients after treatment","volume":"122","author":"Russo","year":"2016","journal-title":"Oral. Surg. Oral. Med Oral. Pathol. Oral. Radio."},{"issue":"10","key":"10.1016\/j.mrrev.2025.108580_bib174","doi-asserted-by":"crossref","first-page":"7109","DOI":"10.3390\/curroncol29100559","article-title":"Psychoneurological Symptoms and Biomarkers of Stress and Inflammation in Newly Diagnosed Head and Neck Cancer Patients: A Network Analysis","volume":"29","author":"Santoso","year":"2022","journal-title":"Curr. Oncol."},{"issue":"7","key":"10.1016\/j.mrrev.2025.108580_bib175","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/cbin.12016","article-title":"The roles of ATP-binding cassette transporter A1 and its substrate cholesterol in head and neck cancers","volume":"47","author":"Sanli","year":"2023","journal-title":"Cell Biol. Int"},{"issue":"1","key":"10.1016\/j.mrrev.2025.108580_bib176","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/s11033-025-10321-9","article-title":"The impact of the ATP-binding cassette (ABC) transporter family on multidrug resistance in head and neck tumors","volume":"52","author":"Zhang","year":"2025","journal-title":"Mol. Biol. Rep."},{"issue":"6","key":"10.1016\/j.mrrev.2025.108580_bib177","doi-asserted-by":"crossref","first-page":"722","DOI":"10.3892\/etm.2022.11658","article-title":"ABCG2, CD44 and SOX9 are increased with the acquisition of drug resistance and involved in cancer stem cell activities in head and neck squamous cell carcinoma cells","volume":"24","author":"Murakami","year":"2022","journal-title":"Exp. Ther. Med"},{"issue":"3","key":"10.1016\/j.mrrev.2025.108580_bib178","first-page":"2220","article-title":"M\u00fcller-Richter UDA: Multi-kinase inhibitors and cisplatin for head and neck cancer treatment in vitro","volume":"18","author":"Brands","year":"2019","journal-title":"Oncol. Lett."},{"issue":"2","key":"10.1016\/j.mrrev.2025.108580_bib179","doi-asserted-by":"crossref","first-page":"631","DOI":"10.3892\/ol.2015.3359","article-title":"Significance of ATP-binding cassette transporter proteins in multidrug resistance of head and neck squamous cell carcinoma","volume":"10","author":"Guan","year":"2015","journal-title":"Oncol. Lett."},{"issue":"7","key":"10.1016\/j.mrrev.2025.108580_bib180","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S1368-8375(01)00028-8","article-title":"Genetic polymorphism of CYP1A1, GSTM1 and GSTT1 genes in Indian oral cancer","volume":"37","author":"Sreelekha","year":"2001","journal-title":"Oral. Oncol."},{"issue":"1","key":"10.1016\/j.mrrev.2025.108580_bib181","doi-asserted-by":"crossref","first-page":"24","DOI":"10.4103\/ijc.IJC_277_17","article-title":"Multiple logistic regression analysis predicts cancer risk among tobacco usage with glutathione S-transferase p1 genotyping in patients with head and neck cancer","volume":"56","author":"Anuradha","year":"2019","journal-title":"Indian J. Cancer"},{"issue":"10Pt1","key":"10.1016\/j.mrrev.2025.108580_bib182","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1097\/00005537-200010000-00013","article-title":"Glutathione S-transferase pi in squamous cell carcinoma of the head and neck","volume":"110","author":"Bentz","year":"2000","journal-title":"Laryngoscope"},{"issue":"3","key":"10.1016\/j.mrrev.2025.108580_bib183","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/(SICI)1097-0215(19990621)84:3<220::AID-IJC4>3.0.CO;2-S","article-title":"Glutathione-S-transferase polymorphisms and risk of squamous-cell carcinoma of the head and neck","volume":"84","author":"Cheng","year":"1999","journal-title":"Int J. Cancer"},{"issue":"3","key":"10.1016\/j.mrrev.2025.108580_bib184","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/hed.20141","article-title":"Glutathione S-transferase polymorphisms and survival from head and neck cancer","volume":"27","author":"Geisler","year":"2005","journal-title":"Head. Neck"},{"issue":"3","key":"10.1016\/j.mrrev.2025.108580_bib185","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1080\/1354750X.2018.1556337","article-title":"How many copies of GSTM1 and GSTT1 are associated with head and neck cancer risk?","volume":"24","author":"Firigato","year":"2019","journal-title":"Biomarkers"},{"issue":"6","key":"10.1016\/j.mrrev.2025.108580_bib186","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.31557\/APJCP.2020.21.6.1637","article-title":"Glutathione S-transferase Polymorphisms in Head and Neck Squamous Cell Carcinoma Treated with Chemotherapy and\/or Radiotherapy","volume":"21","author":"Maniglia","year":"2020","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"4","key":"10.1016\/j.mrrev.2025.108580_bib187","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000444608","article-title":"Clinical Management of Head and Neck Cancer Cases: Role of Pharmacogenetics of CYP2 and GSTs","volume":"39","author":"Ruwali","year":"2016","journal-title":"Oncol. Res Treat."},{"issue":"1","key":"10.1016\/j.mrrev.2025.108580_bib188","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.oraloncology.2009.09.005","article-title":"Oral cancer and polymorphism of ethanol metabolising genes","volume":"46","author":"Marichalar-Mendia","year":"2010","journal-title":"Oral. Oncol."},{"issue":"9","key":"10.1016\/j.mrrev.2025.108580_bib189","first-page":"1061","article-title":"Genetic variants in CYP and GST genes, smoking and risk for head and neck cancers: a gene-environment interaction hospital-based case-control study among Canadian Caucasians","volume":"40","author":"ThekkePurakkal","year":"2019","journal-title":"Carcinogenesis"},{"issue":"6","key":"10.1016\/j.mrrev.2025.108580_bib190","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/em.22098","article-title":"Association of cytochrome P450 1B1 haplotypes with head and neck cancer risk","volume":"58","author":"Katiyar","year":"2017","journal-title":"Environ. Mol. Mutagen"},{"issue":"11","key":"10.1016\/j.mrrev.2025.108580_bib191","first-page":"4398","article-title":"Association of CYP1B1 codon 432 mutant allele in head and neck squamous cell cancer is reflected by somatic mutations of p53 in tumor tissue","volume":"61","author":"Ko","year":"2001","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.mrrev.2025.108580_bib192","doi-asserted-by":"crossref","first-page":"40","DOI":"10.4103\/0973-1482.95172","article-title":"CYP 2D6 polymorphism: a predictor of susceptibility and response to chemoradiotherapy in head and neck cancer","volume":"8","author":"Shukla","year":"2012","journal-title":"J. Cancer Res Ther."},{"issue":"1","key":"10.1016\/j.mrrev.2025.108580_bib193","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12967-018-1418-6","article-title":"Identification and validation a TGF-\u03b2-associated long non-coding RNA of head and neck squamous cell carcinoma by bioinformatics method","volume":"16","author":"Huang","year":"2018","journal-title":"J. Transl. Med"},{"issue":"8","key":"10.1016\/j.mrrev.2025.108580_bib194","doi-asserted-by":"crossref","DOI":"10.3390\/cells9081828","article-title":"Gene Expression Clustering and Selected Head and Neck Cancer Gene Signatures Highlight Risk Probability Differences in Oral Premalignant Lesions","volume":"9","author":"Carenzo","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.mrrev.2025.108580_bib195","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/jcb.240531027","article-title":"TGF-alpha and EGFR in head and neck cancer","volume":"17f","author":"Grandis","year":"1993","journal-title":"J. Cell Biochem Suppl."},{"issue":"3","key":"10.1016\/j.mrrev.2025.108580_bib196","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1111\/odi.14594","article-title":"Targeting TGF beta receptor 1 in head and neck squamous cell carcinoma","volume":"30","author":"Jank","year":"2024","journal-title":"Oral. Dis."},{"issue":"5","key":"10.1016\/j.mrrev.2025.108580_bib197","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00262-024-03672-y","article-title":"TGF-\u03b21 and TGF-\u03b2R1 variants are associated with clinical outcomes in smoking-related head and neck cancer patients treated with chemoradiation through modulating microRNA-mediated regulation","volume":"73","author":"Niu","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"issue":"5","key":"10.1016\/j.mrrev.2025.108580_bib198","doi-asserted-by":"crossref","DOI":"10.3390\/cells13050397","article-title":"Neoadjuvant Radiochemotherapy Alters the Immune and Metabolic Microenvironment in Oral Cancer-Analyses of CD68, CD163, TGF-\u03b21, GLUT-1 and HIF-1\u03b1 Expressions","volume":"13","author":"Weber","year":"2024","journal-title":"Cells"},{"issue":"31","key":"10.1016\/j.mrrev.2025.108580_bib199","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.2217\/fon-2022-0750","article-title":"Role of genetic variations of DNA damage response pathway genes and heat-shock proteins in increased head and neck cancer risk","volume":"18","author":"Mahjabeen","year":"2022","journal-title":"Future Oncol."},{"issue":"11","key":"10.1016\/j.mrrev.2025.108580_bib200","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007627","article-title":"PER2 binding to HSP90 enhances immune response against oral squamous cell carcinoma by inhibiting IKK\/NF-\u03baB pathway and PD-L1 expression","volume":"11","author":"Zhang","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"3","key":"10.1016\/j.mrrev.2025.108580_bib201","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.otorri.2015.03.002","article-title":"HSP-90 expression as a predictor of response to radiotherapy in head and neck cancer patients","volume":"67","author":"Garc\u00eda Lorenzo","year":"2016","journal-title":"Acta Otorrinolaringol. Esp."},{"issue":"1","key":"10.1016\/j.mrrev.2025.108580_bib202","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12885-017-3084-0","article-title":"HSP90 inhibition sensitizes head and neck cancer to platin-based chemoradiotherapy by modulation of the DNA damage response resulting in chromosomal fragmentation","volume":"17","author":"McLaughlin","year":"2017","journal-title":"BMC Cancer"},{"issue":"8","key":"10.1016\/j.mrrev.2025.108580_bib203","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adk3663","article-title":"HSP90 inhibition suppresses tumor glycolytic flux to potentiate the therapeutic efficacy of radiotherapy for head and neck cancer","volume":"10","author":"Chen","year":"2024","journal-title":"Sci. Adv."},{"issue":"5","key":"10.1016\/j.mrrev.2025.108580_bib204","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s00432-024-05779-2","article-title":"Identification of immunogenic cell death-related damage-related molecular patterns (DAMPs) to predict outcomes in patients with head and neck squamous cell carcinoma","volume":"150","author":"Zhang","year":"2024","journal-title":"J. Cancer Res Clin. Oncol."},{"issue":"4","key":"10.1016\/j.mrrev.2025.108580_bib205","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ijom.2008.01.004","article-title":"Overexpression of COX-2 gene in oral cancer is independent of stage of disease and degree of differentiation","volume":"37","author":"Pandey","year":"2008","journal-title":"Int J. Oral. Maxillofac. Surg."},{"issue":"21","key":"10.1016\/j.mrrev.2025.108580_bib206","doi-asserted-by":"crossref","first-page":"6867","DOI":"10.1158\/0008-5472.CAN-11-2460","article-title":"TNF-\u03b1 promotes c-REL\/\u0394Np63\u03b1 interaction and TAp73 dissociation from key genes that mediate growth arrest and apoptosis in head and neck cancer","volume":"71","author":"Lu","year":"2011","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.mrrev.2025.108580_bib207","first-page":"531","volume":"28","author":"Mlak","year":"2020","journal-title":"Support Care Cancer"},{"issue":"8","key":"10.1016\/j.mrrev.2025.108580_bib208","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1007\/s00432-018-2679-4","article-title":"Relationship between TNF-\u03b1 -1031T\/C gene polymorphism, plasma level of TNF-\u03b1, and risk of cachexia in head and neck cancer patients","volume":"144","author":"Powr\u00f3zek","year":"2018","journal-title":"J. Cancer Res Clin. Oncol."},{"issue":"25","key":"10.1016\/j.mrrev.2025.108580_bib209","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000007298","article-title":"No association of TNF-\u03b1-308G\/A polymorphisms with head and neck cancer risk: A PRISMA-compliant meta-analysis","volume":"96","author":"Yuan","year":"2017","journal-title":"Medicine"},{"issue":"1","key":"10.1016\/j.mrrev.2025.108580_bib210","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-95160-x","article-title":"Comprehensive analysis of the expression and prognosis for TNFAIPs in head and neck cancer","volume":"11","author":"Lan","year":"2021","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.mrrev.2025.108580_bib211","first-page":"123","article-title":"Oncoapoptotic signaling and deregulated target genes in cancers: special reference to oral cancer","volume":"1836","author":"Khan","year":"2013","journal-title":"Biochim Biophys. Acta"},{"issue":"1","key":"10.1016\/j.mrrev.2025.108580_bib212","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1186\/s13046-024-03255-w","article-title":"SPP1+\u2009macrophages promote head and neck squamous cell carcinoma progression by secreting TNF-\u03b1 and IL-1\u03b2","volume":"43","author":"Liu","year":"2024","journal-title":"J. Exp. Clin. Cancer Res"},{"issue":"11","key":"10.1016\/j.mrrev.2025.108580_bib213","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1158\/2767-9764.CRC-24-0274","article-title":"Functional RNAi screening identifies G2\/M and kinetochore components as modulators of TNF\u03b1\/NF-\u03baB prosurvival signaling in head and neck squamous cell carcinoma","volume":"4","author":"Morgan","year":"2024","journal-title":"Cancer Res Commun."},{"issue":"4","key":"10.1016\/j.mrrev.2025.108580_bib214","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0300437","article-title":"Expression of Toll-like receptors in oral squamous cell carcinoma","volume":"19","author":"Rusanen","year":"2024","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.mrrev.2025.108580_bib215","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41416-018-0351-z","article-title":"Co-targeting EGFR and IKK\u03b2\/NF-\u03baB signalling pathways in head and neck squamous cell carcinoma: a potential novel therapy for head and neck squamous cell cancer","volume":"120","author":"Li","year":"2019","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.mrrev.2025.108580_bib216","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202001455R","article-title":"Crosstalk between head and neck cancer cells and lymphatic endothelial cells promotes tumor metastasis via CXCL5-CXCR2 signaling","volume":"35","author":"Lee","year":"2021","journal-title":"Faseb J."},{"issue":"30","key":"10.1016\/j.mrrev.2025.108580_bib217","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000029378","article-title":"Expression of chemokine CXCL8\/9\/10\/11\/13 and its prognostic significance in head and neck cancer","volume":"101","author":"Zhao","year":"2022","journal-title":"Medicine"},{"issue":"7","key":"10.1016\/j.mrrev.2025.108580_bib218","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1001\/archotol.1994.01880310059011","article-title":"H-ras oncogene mutation and human papillomavirus infection in oral carcinomas","volume":"120","author":"Anderson","year":"1994","journal-title":"Arch. Otolaryngol. Head. Neck Surg."},{"issue":"2","key":"10.1016\/j.mrrev.2025.108580_bib219","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1158\/0008-5472.CAN-03-3284","article-title":"Human papillomavirus type 16 and TP53 mutation in oral cancer: matched analysis of the IARC multicenter study","volume":"64","author":"Dai","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.mrrev.2025.108580_bib220","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3389\/fonc.2018.00265","article-title":"Epstein-Barr Virus-Associated Malignancies: Roles of Viral Oncoproteins in Carcinogenesis","volume":"8","author":"El-Sharkawy","year":"2018","journal-title":"Front Oncol."},{"issue":"4","key":"10.1016\/j.mrrev.2025.108580_bib221","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/odi.12656","article-title":"Epstein-Barr virus in the pathogenesis of oral cancers","volume":"24","author":"Guidry","year":"2018","journal-title":"Oral. Dis."},{"issue":"3","key":"10.1016\/j.mrrev.2025.108580_bib222","doi-asserted-by":"crossref","DOI":"10.4238\/gmr.15038206","article-title":"Characterization of gene methylation in human papillomavirus associated-head and neck squamous cell carcinoma","volume":"15","author":"Zhang","year":"2016","journal-title":"Genet Mol. Res"},{"issue":"3","key":"10.1016\/j.mrrev.2025.108580_bib223","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1042\/BST20253041","article-title":"Advances in understanding the mechanisms of the human papillomavirus oncoproteins","volume":"53","author":"Obanya","year":"2025","journal-title":"Biochem Soc. Trans."},{"issue":"1","key":"10.1016\/j.mrrev.2025.108580_bib224","doi-asserted-by":"crossref","first-page":"191","DOI":"10.31557\/APJCP.2022.23.1.191","article-title":"Exome Sequencing with Validations and Expression of p16\/CDKN2A Shows no Association with HPV in Oral Cancers","volume":"23","author":"Shyamsundar","year":"2022","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"1","key":"10.1016\/j.mrrev.2025.108580_bib225","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41392-022-01297-0","article-title":"Targeted therapy for head and neck cancer: signaling pathways and clinical studies","volume":"8","author":"Li","year":"2023","journal-title":"Signal Transduct. Target Ther."},{"issue":"5","key":"10.1016\/j.mrrev.2025.108580_bib226","first-page":"7497","article-title":"Grzybowska-Szatkowska L: Application of molecular targeted therapies in the treatment of head and neck squamous cell carcinoma","volume":"15","author":"Kozakiewicz","year":"2018","journal-title":"Oncol. Lett."},{"issue":"8","key":"10.1016\/j.mrrev.2025.108580_bib227","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1093\/annonc\/mdw204","article-title":"Phase II randomized trial of radiation therapy, cetuximab, and pemetrexed with or without bevacizumab in patients with locally advanced head and neck cancer","volume":"27","author":"Argiris","year":"2016","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.mrrev.2025.108580_bib228","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1093\/annonc\/mds245","article-title":"Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck","volume":"24","author":"Argiris","year":"2013","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.mrrev.2025.108580_bib229","doi-asserted-by":"crossref","DOI":"10.3390\/genes8010035","article-title":"Integrative miRNA-gene expression analysis enables refinement of associated biology and prediction of response to cetuximab in head and neck squamous cell cancer","volume":"8","author":"De Cecco","year":"2017","journal-title":"Genes"},{"issue":"1","key":"10.1016\/j.mrrev.2025.108580_bib230","first-page":"E566","article-title":"Phase II trial of bevacizumab\u2009+\u2009cetuximab\u2009+\u2009cisplatin with concurrent intensity-modulated radiation therapy for patients with stage III\/IVB head and neck squamous cell carcinoma","volume":"38","author":"Fury","year":"2016","journal-title":"Head. Neck"},{"issue":"11","key":"10.1016\/j.mrrev.2025.108580_bib231","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1158\/1078-0432.CCR-13-2721","article-title":"RAS\/PI3K crosstalk and cetuximab resistance in head and neck squamous cell carcinoma","volume":"20","author":"Rampias","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.mrrev.2025.108580_bib232","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1093\/annonc\/mdx344","article-title":"Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and\/or metastatic head and neck cancer","volume":"28","author":"Cohen","year":"2017","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.mrrev.2025.108580_bib233","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/COC.0000000000000317","article-title":"Phase I Trial Using Induction Ciplatin, Docetaxel, 5-FU and Erlotinib Followed by Cisplatin, Bevacizumab and Erlotinib With Concurrent Radiotherapy for Advanced Head and Neck Cancer","volume":"41","author":"Ahn","year":"2018","journal-title":"Am. J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.mrrev.2025.108580_bib234","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1470-2045(09)70002-6","article-title":"Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I\/II study","volume":"10","author":"Cohen","year":"2009","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.mrrev.2025.108580_bib235","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/PPO.0b013e3182329791","article-title":"Combined modality treatment with chemotherapy, radiation therapy, bevacizumab, and erlotinib in patients with locally advanced squamous carcinoma of the head and neck: a phase II trial of the Sarah Cannon oncology research consortium","volume":"17","author":"Hainsworth","year":"2011","journal-title":"Cancer J."},{"issue":"5","key":"10.1016\/j.mrrev.2025.108580_bib236","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/1078-0432.CCR-11-1982","article-title":"Prospective trial of synchronous bevacizumab, erlotinib, and concurrent chemoradiation in locally advanced head and neck cancer","volume":"18","author":"Yoo","year":"2012","journal-title":"Clin. Cancer Res"},{"issue":"35","key":"10.1016\/j.mrrev.2025.108580_bib237","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.1200\/JCO.2015.61.4370","volume":"33","author":"Harrington","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.mrrev.2025.108580_bib238","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1200\/JCO.2010.33.3591","article-title":"Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer","volume":"29","author":"Argiris","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"34","key":"10.1016\/j.mrrev.2025.108580_bib239","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1200\/JCO.19.00555","article-title":"Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer","volume":"37","author":"Argiris","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"20","key":"10.1016\/j.mrrev.2025.108580_bib240","doi-asserted-by":"crossref","first-page":"5008","DOI":"10.1002\/cncr.27498","article-title":"A phase 2 study of bevacizumab with cisplatin plus intensity-modulated radiation therapy for stage III\/IVB head and neck squamous cell cancer","volume":"118","author":"Fury","year":"2012","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.mrrev.2025.108580_bib241","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1002\/hed.23813","article-title":"Phase II study of bevacizumab in combination with docetaxel and radiation in locally advanced squamous cell carcinoma of the head and neck","volume":"37","author":"Yao","year":"2015","journal-title":"Head. Neck"},{"issue":"24","key":"10.1016\/j.mrrev.2025.108580_bib242","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1200\/JCO.2006.10.2871","article-title":"Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma","volume":"25","author":"Elser","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.mrrev.2025.108580_bib243","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.oraloncology.2014.12.011","article-title":"A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and\/or metastatic head and neck squamous cell carcinoma","volume":"51","author":"Gilbert","year":"2015","journal-title":"Oral. Oncol."},{"issue":"3","key":"10.1016\/j.mrrev.2025.108580_bib244","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/hed.23898","article-title":"Phase II trial evaluating the efficacy of sorafenib (BAY 43-9006) and correlating early fluorodeoxyglucose positron emission tomography-CT response to outcome in patients with recurrent and\/or metastatic head and neck cancer","volume":"38","author":"Lalami","year":"2016","journal-title":"Head. Neck"},{"issue":"20","key":"10.1016\/j.mrrev.2025.108580_bib245","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1200\/JCO.2009.25.6834","article-title":"Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420","volume":"28","author":"Williamson","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.mrrev.2025.108580_bib246","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s10637-009-9296-7","article-title":"Phase II study of sunitinib malate in head and neck squamous cell carcinoma","volume":"28","author":"Choong","year":"2010","journal-title":"Invest N. Drugs"},{"issue":"4","key":"10.1016\/j.mrrev.2025.108580_bib247","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s00280-009-1070-1","article-title":"A phase II study of sunitinib in patients with recurrent and\/or metastatic non-nasopharyngeal head and neck cancer","volume":"65","author":"Fountzilas","year":"2010","journal-title":"Cancer Chemother. Pharm."},{"issue":"1","key":"10.1016\/j.mrrev.2025.108580_bib248","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1200\/JCO.2009.23.8584","article-title":"Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01","volume":"28","author":"Machiels","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.mrrev.2025.108580_bib249","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/PPO.0000000000000617","article-title":"The potential for selective cyclin-dependent kinase 4\/6 inhibition in the therapy for head and neck squamous cell carcinoma","volume":"28","author":"Adkins","year":"2022","journal-title":"Cancer J."},{"issue":"9","key":"10.1016\/j.mrrev.2025.108580_bib250","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S1470-2045(19)30405-X","article-title":"Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial","volume":"20","author":"Adkins","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.mrrev.2025.108580_bib251","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2021.105192","article-title":"Palbociclib and cetuximab compared with placebo and cetuximab in platinum-resistant, cetuximab-na\u00efve, human papillomavirus-unrelated recurrent or metastatic head and neck squamous cell carcinoma: A double-blind, randomized, phase 2 trial","volume":"115","author":"Adkins","year":"2021","journal-title":"Oral. Oncol."},{"key":"10.1016\/j.mrrev.2025.108580_bib252","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2022.106219","article-title":"A phase I study of avelumab, palbociclib, and cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma","volume":"135","author":"Dennis","year":"2022","journal-title":"Oral. Oncol."},{"issue":"2","key":"10.1016\/j.mrrev.2025.108580_bib253","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1158\/1078-0432.CCR-23-2303","article-title":"A Phase I Study of the CDK4\/6 Inhibitor Palbociclib in Combination with Cetuximab and Radiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma","volume":"30","author":"Ngamphaiboon","year":"2024","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.mrrev.2025.108580_bib254","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2020.105164","article-title":"Palbociclib and cetuximab in cetuximab-resistant human papillomavirus-related oropharynx squamous-cell carcinoma: A multicenter phase 2 trial","volume":"114","author":"Oppelt","year":"2021","journal-title":"Oral. Oncol."},{"key":"10.1016\/j.mrrev.2025.108580_bib255","article-title":"Palbociclib, a Selective CDK4\/6 inhibitor, administered before and after chemoradiotherapy for human papillomavirus-negative, locally advanced head and neck squamous cell carcinoma: a single-arm, phase II trial","volume":"9","author":"Oppelt","year":"2025","journal-title":"JCO Precis Oncol."},{"issue":"5","key":"10.1016\/j.mrrev.2025.108580_bib256","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1007\/s10637-020-00898-2","article-title":"A multi-center phase II trial evaluating the efficacy of palbociclib in combination with carboplatin for the treatment of unresectable recurrent or metastatic head and neck squamous cell carcinoma","volume":"38","author":"Swiecicki","year":"2020","journal-title":"Invest N. Drugs"},{"key":"10.1016\/j.mrrev.2025.108580_bib257","article-title":"Palbociclib in patients with head and neck cancer and other tumors with CDKN2A Alterations: results from the targeted agent and profiling utilization registry study","volume":"8","author":"Worden","year":"2024","journal-title":"JCO Precis Oncol."},{"issue":"10","key":"10.1016\/j.mrrev.2025.108580_bib258","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1158\/1535-7163.MCT-21-0067","article-title":"SLC7A11 Is a Superior Determinant of APR-246 (Eprenetapopt) Response than TP53 Mutation Status","volume":"20","author":"Fujihara","year":"2021","journal-title":"Mol. Cancer Ther."},{"issue":"5","key":"10.1016\/j.mrrev.2025.108580_bib259","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1200\/JCO.22.02786","article-title":"Personalized biomarker-based umbrella trial for patients with recurrent or metastatic head and neck squamous cell carcinoma: KCSG HN 15-16 TRIUMPH trial","volume":"42","author":"Keam","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"20","key":"10.1016\/j.mrrev.2025.108580_bib260","doi-asserted-by":"crossref","first-page":"4949","DOI":"10.1158\/1078-0432.CCR-18-0467","article-title":"Final report of a phase I trial of Olaparib with Cetuximab and radiation for heavy smoker patients with locally advanced head and neck cancer","volume":"24","author":"Karam","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.mrrev.2025.108580_bib261","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1158\/2767-9764.CRC-23-0051","article-title":"Phase II window study of olaparib alone or with Cisplatin or Durvalumab in operable head and neck cancer","volume":"3","author":"Moutafi","year":"2023","journal-title":"Cancer Res Commun."},{"issue":"Pt 2","key":"10.1016\/j.mrrev.2025.108580_bib262","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.semcancer.2018.01.008","article-title":"Head and neck squamous cell carcinoma: genomics and emerging biomarkers for immunomodulatory cancer treatments","volume":"52","author":"Solomon","year":"2018","journal-title":"Semin Cancer Biol."},{"issue":"11","key":"10.1016\/j.mrrev.2025.108580_bib263","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1093\/annonc\/mdy411","article-title":"Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial","volume":"29","author":"Colevas","year":"2018","journal-title":"Ann. Oncol."},{"issue":"18","key":"10.1016\/j.mrrev.2025.108580_bib264","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1001\/jama.2025.1483","article-title":"Atezolizumab in High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical Trial","volume":"333","author":"Haddad","year":"2025","journal-title":"Jama"},{"issue":"7","key":"10.1016\/j.mrrev.2025.108580_bib265","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.annonc.2020.04.001","article-title":"Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study","volume":"31","author":"Ferris","year":"2020","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.mrrev.2025.108580_bib266","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1200\/JCO.22.00332","article-title":"Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent\/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651","volume":"41","author":"Haddad","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.mrrev.2025.108580_bib267","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13045-025-01669-3","article-title":"First-in-human evaluation of memory-like NK cells with an IL-15 super-agonist and CTLA-4 blockade in advanced head and neck cancer","volume":"18","author":"Shapiro","year":"2025","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.mrrev.2025.108580_bib268","doi-asserted-by":"crossref","first-page":"7348","DOI":"10.1038\/s41467-021-26472-9","article-title":"Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma","volume":"12","author":"Vos","year":"2021","journal-title":"Nat. Commun."},{"issue":"13","key":"10.1016\/j.mrrev.2025.108580_bib269","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1002\/cam4.4593","article-title":"Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head-and-neck cancer","volume":"11","author":"Doki","year":"2022","journal-title":"Cancer Med."},{"issue":"10","key":"10.1016\/j.mrrev.2025.108580_bib270","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1158\/1078-0432.CCR-23-3249","article-title":"A phase II open-label randomized clinical trial of preoperative Durvalumab or Durvalumab plus Tremelimumab in resectable head and neck squamous cell carcinoma","volume":"30","author":"Kim","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.mrrev.2025.108580_bib271","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.4143\/crt.2023.502","article-title":"Phase II trial of combined durvalumab plus tremelimumab with proton therapy for recurrent or metastatic head and neck squamous cell carcinoma","volume":"55","author":"Kim","year":"2023","journal-title":"Cancer Res. Treat."},{"key":"10.1016\/j.mrrev.2025.108580_bib272","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.532285","article-title":"Overcoming limitations of cisplatin therapy by additional treatment with the HSP90 inhibitor onalespib","volume":"10","author":"Mortensen","year":"2020","journal-title":"Front. Oncol."},{"issue":"5","key":"10.1016\/j.mrrev.2025.108580_bib273","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.ijrobp.2021.03.048","article-title":"Pharmacological inhibition of HSP90 radiosensitizes head and neck squamous cell carcinoma xenograft by inhibition of DNA damage repair, nucleotide metabolism, and radiation-induced tumor vasculogenesis","volume":"110","author":"Naz","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"14","key":"10.1016\/j.mrrev.2025.108580_bib274","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1002\/cncr.25786","article-title":"Phase 1 trial of concurrent erlotinib, celecoxib, and reirradiation for recurrent head and neck cancer","volume":"117","author":"Kao","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.mrrev.2025.108580_bib275","article-title":"Triple Oral Metronomic Chemotherapy Versus Chemotherapy of Physician Discretion After Failure of Platinum-Based Therapy in Advanced Head and Neck Cancer: A Phase III Randomized Study (METRO-CHASE Study)","volume":"11","author":"Kapoor","year":"2025","journal-title":"JCO Glob. Oncol."},{"issue":"1","key":"10.1016\/j.mrrev.2025.108580_bib276","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/hed.20662","article-title":"Results of a pilot study of the effects of celecoxib on cancer cachexia in patients with cancer of the head, neck, and gastrointestinal tract","volume":"30","author":"Lai","year":"2008","journal-title":"Head. Neck"},{"issue":"3","key":"10.1016\/j.mrrev.2025.108580_bib277","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1158\/1940-6207.CAPR-13-0215","article-title":"Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study","volume":"7","author":"Saba","year":"2014","journal-title":"Cancer Prev Res (Phila)"},{"issue":"17","key":"10.1016\/j.mrrev.2025.108580_bib278","doi-asserted-by":"crossref","first-page":"5755","DOI":"10.1158\/1078-0432.CCR-11-0861","article-title":"Early tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab, and radiotherapy for head and neck cancer","volume":"17","author":"Argiris","year":"2011","journal-title":"Clin. Cancer Res"},{"issue":"15","key":"10.1016\/j.mrrev.2025.108580_bib279","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1002\/cncr.25852","article-title":"A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303)","volume":"117","author":"Argiris","year":"2011","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.mrrev.2025.108580_bib280","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1093\/annonc\/mdp390","article-title":"Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and\/or metastatic head and neck squamous cell carcinoma","volume":"21","author":"Chung","year":"2010","journal-title":"Ann. Oncol."},{"issue":"7","key":"10.1016\/j.mrrev.2025.108580_bib281","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1002\/hed.23046","volume":"35","author":"Gilbert","year":"2013","journal-title":"Head. Neck"},{"issue":"4","key":"10.1016\/j.mrrev.2025.108580_bib282","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.ijrobp.2011.09.023","article-title":"Phase I trial using the proteasome inhibitor bortezomib and concurrent chemoradiotherapy for head-and-neck malignancies","volume":"83","author":"Kubicek","year":"2012","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.mrrev.2025.108580_bib283","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.radonc.2022.04.006","article-title":"Development and validation of a 6-gene signature for the prognosis of loco-regional control in patients with HPV-negative locally advanced HNSCC treated by postoperative radio(chemo)therapy","volume":"171","author":"Patil","year":"2022","journal-title":"Radio. Oncol."}],"container-title":["Mutation Research - Reviews in Mutation Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1383574225000511?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1383574225000511?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T04:12:48Z","timestamp":1781323968000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1383574225000511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":283,"alternative-id":["S1383574225000511"],"URL":"https:\/\/doi.org\/10.1016\/j.mrrev.2025.108580","relation":{},"ISSN":["1383-5742"],"issn-type":[{"value":"1383-5742","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unveiling oral cancer\u2019s molecular blueprint: A novel classification to guide precision therapy","name":"articletitle","label":"Article Title"},{"value":"Mutation Research - Reviews in Mutation Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mrrev.2025.108580","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108580"}}